Pilbara Exploration Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Morgan Stanley Reiterates Equalweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
June 23, 2025 1:35 PM EDTMorgan Stanley analyst Thibault Boutherin reiterated an Equalweight rating and DKK550.00 price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO).
The analyst comments "H&H partnership termination (see press release here): Novo entered the arrangement with H&H before the 22 May (date of removal of sema from FDA shortage list) in order to facilitate the transition of patients on compounded semaglutide to Wegovy. Management reiterated that mass compounding and mass personalisation are against Novo's values and the direction they see for the market in the long term, and stated that Novo will not... More
